23 November 2016
Highlights in Medicinal Chemistry II
Organised by:
SCI’s Fine Chemicals Group
SCI, London, UK
Registration Closed
This event is no longer available for registration.
Share this event
Synopsis
This meeting aims to showcase vignettes of modern medicinal chemistry to bring new thinking to the subject, challenge perceptions and encourage scientific interaction between researchers. The short presentation format of the meeting also aims to provide a focused forum to promote examples of medicinal chemistry excellence.Attendees
This meeting is targeted at academic and industrial scientists engaged in all aspects of the drug discovery process and those interested in broadening their knowledge at the forefront of medicinal chemistry.Programme
Day 1 - 23 November 2016
- 09:00
- Registration and refreshments
- 09:50
- Opening remarks
- 09:55
- The realisation of activity-directed synthesis Prof Adam Nelson, University of Leeds
- 10:35
- Structure-based design of drug-like macrocycles to probe the role of MTH1 in cancer Dr Jason Kettle, AstraZeneca
- 11:15
- Refreshment break
- 11:35
- Development of novel, selective and irreversible PI3K inhibitors Mr Samuel Dalton, University of Strathclyde, GlaxoSmithKline
- 12:00
- Discovery of the first cell-active inhibitors of poly(ADP ribose) glycohydrolase (PARG) through high-throughput screening and computational approaches Dr Kate Smith, Cancer Research UK Manchester Institute
- 12:25
- Discovery of a small molecule that mitigates hearing loss in a model of Usher syndrome III Dr Karine Malagu, Discovery from Charles River
- 12:50
- Lunch
- 13:50
- Discovery of novel TACE inhibitors for topical treatment of psoriasis Dr Gilles Ouvry, Galderma
- 14:15
- Discovery of CCT251921: A potent, selective and orally bioavailable small molecule modulator of the mediator complex-associated kinases CDK8 and CDK19 Dr Aurélie Mallinger, The Institute of Cancer Research
- 14:40
- Increasing solubility for free Dr Timothy Ritchie, TJR-Chem
- 15:20
- Refreshment break
- 15:40
- Extracting actionable knowledge from large scale in vitro pharmacology data Dr Al Dossetter, MedChemica
- 16:05
- Receptor kinetics vs CNS exposure: which is more important for a ghrelin inverse agonist Dr William McCoull, AstraZeneca
- 16:30
- Chemical probes for epigenetic proteins Prof Paul Brennan, University of Oxford
- 17:10
- Closing remarks
- 17:15
- Wine reception
Accessibility Grants
SCI accessibility grants are available to support SCI members with disabilities, long term health conditions, those who require a carer, and members who are nursing parents to attend SCI events. Download an application form to apply for a grant.
Venue and Contact
SCI
14/15 Belgrave Square
London
SW1X 8PS
Conference Team
Tel: +44 (0)20 7598 1561
Email: conferences@soci.org
Fees
Early Bird fee - before 7 October 2016
GB£90 . . . . . . . . . SCI Member
GB£40. . . . . . . . . .SCI Student Member
GB£130 . . . . . . . . Non Member
GB£110. . . . . . . . .SCI Member
GB£50. . . . . . . . . .SCI Student Member
GB£155. . . . . . . . .Non Member
Become an SCI Member and save on this and future events
See Membership OptionsSign up as an Event Member to join this event. SCI Full or Student Members receive discounts on event registrations
Booking Process/Deadlines
For booking terms and conditions click here.
Sponsors
Additional Info
Organising Committee
Joanne Pinder, SCI/Vertex Pharmaceuticals Eur Ltd
Sarah Major, SCI/Evotec (UK) Ltd
Iain Simpson, SCI/AstraZeneca
Mihiro Sunose, SCI/Sygnature Discovery Ltd
Nigel Swain, SCI/Pfizer